News and Announcements
Novogen Edison Investment Research Report
- Published May 23, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Novegen (ASX: NRT) is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. Headquartered in Sydney, Australia, Novogen collaborates with leading scientists, clinicians, and investors around the world. Novogen’s recent market updates presented mixed news for investors.
KEY TAKEAWAYS:
- Recruitment in the Cantrixil Phase I is underway and preparations for the Phase II trial.
- Mixed data from preclinical studies have seen development terminated for Anisina, which had been expected to enter the clinic in H217.
- While the termination of Anisina is disappointing, it is encouraging to see that management is taking a disciplined approach to assessing pipeline products.
- Now valued, Novogen is between A$86m (A$0.18/share) and A$146m (A$0.30/share) under two different development scenarios for GDC-0084.
- Major milestones anticipated in 2017 include initiation of a Phase II trial of GDC-0084 and full enrolment in the Cantrixil Phase I.
Company Updates
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Everything is now competing for the same dollar
Key takeaways As recently as 2022, Germany and Japan could borrow for 30 years at close to zero. That world is gone, and AI is now bidding for what is left. Over the past fortnight, I listened to founders, operators and allocators describe where their industries are heading. They covered four very different frontiers. Each […]
Australia has not held 90 days of fuel since 2012. The fix may start at a sewage plant.
A decommissioned council treatment site in Bundaberg is being built into a $188.9 million biorefinery. Its managing director is candid that the largest revenue line is not yet contracted. Australia has not met its international 90-day fuel reserve obligation since 2012. Around 90 per cent of the country’s liquid fuel is imported. Andy Whitmore, Managing […]
Backed By Leading Investment Groups and Family Offices
